De Zhou

De Zhou

Auto-generated profile, based on publicly available information

De Zhou

Department of Hematology, the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang PR China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2025 in Blood
Verified
Journal Article
Open access
DZDe Zhou
De Zhou
XHXianbo Huang
Xianbo Huang
LZLixia Zhu
Lixia Zhu
XHXuelian Hu
Xuelian Hu
XYXiudi Yang
Xiudi Yang
XYXiujin Ye
Xiujin Ye
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome, and the overall survival (OS) of adult patients is poor. Ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor, has shown promise in treating HLH and exerts synergistic effects when combined with dexamethasone. Our pilot study preliminarily demonstrated that the combination of ruxolitinib and dexamethasone (Ru-D regimen) had a high response rate and led to favorable short-term survival outcomes in adult patients with HLH. In this prospective phase 2 clinical trial, we propose the Ru-D regimen as a first-line treatment for adults newly diagnosed as having HLH with unknown triggers. A total of 28 Chinese patients were enrolled, and the median follow-up time was 25.1 months (range, 0.87-34.0). The 2-month OS rate (the primary end point) was 85.7%, which exceeded our expected 2-month OS rate of 75%. The 6-month and 2-year OS rates were 67.9% (19/28) and 53.6% (15/28), respectively. The median OS of patients with lymphoma-associated HLH (LAHS) was 5.8 months, and most of these patients had natural killer/T-cell lymphoma. In contrast, the 2-year OS rate of patients without LAHS was 75%. The overall response rate was 85.7% (24/28); of 28 patients, 5 (17.9%) achieved a complete response during the Ru-D regimen. Overall, the Ru-D regimen was well tolerated in patients with HLH. This study demonstrates the efficacy and safety of the Ru-D regimen in adults newly diagnosed as having HLH with unknown triggers and warrants a phase 3 randomized controlled study. This trial was registered at www.chictr.org.cn as #ChiCTR2100049996).


22 February 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
DZDe Zhou
De Zhou
XHXianbo Huang
Xianbo Huang
MXMixue Xie
Mixue Xie
LZLixia Zhu
Lixia Zhu
XHXin Huang
Xin Huang
XYXiujin Ye
Xiujin Ye

13 May 2020 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
DZDe Zhou
De Zhou
TSTing Shi
Ting Shi
SZShuqi Zhao
Shuqi Zhao
JZJingjing Zhu
Jingjing Zhu
LZLixia Zhu
Lixia Zhu
XYXiujin Ye
Xiujin Ye

1 November 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
DZDe Zhou
De Zhou
WYWenjuan Yu
Wenjuan Yu
MXMixue Xie
Mixue Xie
EGEhsan Ghoushi
Ehsan Ghoushi
XHXuelian Hu
Xuelian Hu
HTHongyan Tong
Hongyan Tong

6 May 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
SZShuqi Zhao
Shuqi Zhao
JWJinghan Wang
Jinghan Wang
YLYinjun Lou
Yinjun Lou
XHXin Huang
Xin Huang
WXWanzhou Xie
Wanzhou Xie
DZDe Zhou
De Zhou